Ocumetics Bionic Lens: Development Updates and Facts
Author: Ian C. Langtree - Writer/Editor for Disabled World (DW)
Published: 7 Sep 2022 - Updated: 18 Sep 2026
Publication Type: News
Table of Contents:
Synopsis - Definition - Overview - FAQs - Insights, Updates - Related Content
Synopsis
This report tracks the development of the Ocumetics Bionic Lens, an expandable accommodative intraocular lens that fits within the eye's natural lens compartment and works with the eye's own muscle activity to shift focus between near and distant objects without glasses or contacts. Created by Dr. Garth Webb through the Canadian firm Ocumetics Technology Corp., the technology aims to restore clear vision at all distances and to prevent cataracts by replacing the natural lens that degrades with age. The material draws its authority from dated company statements attributed to named officers, including CEO updates and the regulatory and medical leads overseeing preclinical work, and it lays out the staged testing path toward first in human trials in plain language. For seniors, people living with low vision, and anyone weighing cataract or refractive options, it offers a clear, chronological account of where this vision correction research actually stands rather than marketing claims, which makes it a useful reference for readers following advances in ophthalmology and eye care.
At a Glance
- 1 - The eight minute implant procedure mirrors standard cataract surgery. Patients would have their sight corrected immediately afterward.
- 2 - Ocumetics Technology Corp. was founded in Canada in 2012 by Dr. Garth Webb. The firm specializes in adaptive lens designs for the ophthalmic industry.
- 3 - The next-generation one-piece lens eliminates all internal interface materials, containing no air, water, or oil. It was manufactured in Germany and shipped to a clinical facility in Mexico City.
- 4 - First-in-human Group One surgeries were performed in Mexico City in Fall 2025, and within one month all patients reached distance vision of 20/40 or better. In one case, a previously legally blind patient regained enough sight to qualify to drive.
Topic Definition
- Bionic Lens
The Bionic Lens is an expandable, accommodating artificial lens built to sit inside the eye's own capsular bag and take the place of the natural lens, which stiffens and clouds with age. Unlike a fixed conventional implant, it flexes along with the ciliary muscle so the eye can move focus smoothly between near and far objects, aiming to deliver sharp vision at every distance without glasses or contacts. Developed by Dr. Garth Webb through Canada's Ocumetics Technology Corp., it is framed as both a vision enhancement and a preventive measure, since replacing the natural lens is meant to rule out any future cataract formation. Having advanced from preclinical work using cadaver donor eyes into first-in-human clinical study, it is still an investigational device that has not yet received regulatory approval or reached commercial availability.
Overview
Imagine being able to see three times better than 20/20 vision without wearing glasses or contacts, even at 100-plus years old, with the help of bionic lenses implanted in your eyes. Imagine seeing the minor details from 30 feet away instead of only 10 feet, such as signs or the clock's time. Futuristic, but possible with the Ocumetics Bionic Lens™.
In 2012, Ocumetics Technology Corp., a Canadian-based research and product development company, was established to produce vision enhancement products and services through advanced refractive technologies invented and developed by Dr. Garth Webb.
Currently, Ocumetics is developing ground-breaking technological advancements for the ophthalmic industry through disruptive technological design in the Bionic Lens™. Its patented design may address many shortcomings of other surgeries and lens replacement options. The Bionic Lens™ is the first to help people recover normal vision at all viewing distances without requiring eyeglasses and lag time in focus.
Ocumetics is developing new lens technology, which is expected to efficiently link electrical impulses with the natural mechanisms for accommodation within the human eye. Through the Bionic Lens™, Ocumetics' goals of contributing to improving quality of life while ensuring that safety and efficacy remain central to every facet relevant to patient care are closer to being realized.
Webb says people with the specialized lenses surgically inserted would never get cataracts because their natural lenses, which decay over time, would have been replaced. He says the painless procedure, identical to cataract surgery, would take about eight minutes, and a patient's sight would be immediately corrected.
Other future possibilities for the Bionic Lens may include:
- Installing a slow drug delivery inside the eye.
- Sharing data with another person with a Bionic Lens.
- Using a projection system so you can view your smartphone screen through your Bionic Lens.
Bionic Lens Updates
September 17th, 2026 : Ocumetics Provides Summary of Group One Patient Clinical Progress
Ocumetics Technology Corp. is pleased to announce that its first-inhuman Group One clinical patients have reached their 12-month follow-up milestone, marking an important point in the Company's clinical development program for its accommodating intraocular lens (the "Ocumetics Lens").
One Month - Meaningful Functional Vision: At approximately one month following surgery, all patients achieved distance vision of 20/40 or better. For patients who entered the study with significant visual impairment, this represented an important improvement in functional vision and provided an early indication that the Ocumetics Lens could be safely implanted and had the potential to deliver meaningful visual benefits.
Three Months - Continued Clinical Progress: At three months following surgery, Group One patient results met or exceeded the Company's predefined internal benchmarks for safety, lens delivery and foundational distance vision performance. The continued improvement observed in Group One patients supported the Company's decision to advance its clinical development program.
Six Months - Vision Translating into Quality of Life: At six months following surgery, Group One patients continued to demonstrate encouraging visual outcomes while the safety profile remained encouraging. Importantly, patients also began describing how improved vision was affecting their everyday lives, including the ability to read more easily, watch television, recognize family members, participate in everyday activities with greater visual independence, and in one case, achieve vision that qualified a previously legally blind patient to drive. For Ocumetics, these experiences highlight the potential impact of its lens technology beyond an eye-chart measurement.
Twelve Months - Follow-Up Visits Represent an Important Next Milestone: Group One patients have now commenced their 12-month follow-up examinations. Longer-term follow-up is an important part of clinical development because it provides additional information regarding the durability of visual outcomes and the ongoing safety and performance of the Ocumetics Lens. Ocumetics looks forward to reporting appropriate clinical information as it becomes available.
The Company emphasizes that these are early first-in-human results. The data should not be interpreted as established proof of safety or efficacy. Additional patients, additional clinical data, longer-term follow-up and further clinical and regulatory evaluation will be required as the Company advances its clinical program.
The Company is now preparing to advance to the next group of patients. Unlike Group One, which focused solely on safety, the primary and secondary purposes of the Group Two surgeries are to study the safety, distance, and near vision performance of the Ocumetics Lens.
September 8th, 2026 : Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries
Ocumetics Technology Corp.has announced that its clinical facility in Mexico City has initiated the patient recruitment process for Group Two of the Company's ongoing human clinical study of its next-generation accommodating intraocular lens (the "Ocumetics Lens").
Following the encouraging clinical experience and positive results observed in Group One patients, the Company is now preparing to advance to the next group of patients. Unlike Group One, which focused solely on safety, the primary and secondary purposes of the Group Two surgeries are to study the safety, distance, and near vision performance of the new Ocumetics accommodating intraocular lens.
The Mexico City clinical facility, which successfully performed Group One surgeries in Fall 2025, has begun the process of identifying and recruiting eligible patients in preparation for the upcoming Fall 2026 surgeries.
Group Two patients will receive Ocumetics' next-generation accommodating intraocular lens, incorporating the Company's latest design advancements. The Ocumetics Lens will be delivered using the Company's enhanced lens delivery system.
The Company's Group One clinical outcomes met and exceeded the Company's expectations regarding the safety, performance and handling of the Ocumetics Lens. Patients have continued to be followed as part of the Company's ongoing clinical evaluation. Twelve-month follow-up visits, representing an important study milestone, are in progress.
September 1st, 2026 : Ocumetics Completes Manufacturing of Next-Generation Lenses
Ocumetics is pleased to announce that it has successfully completed manufacturing of its next-generation solid-state accommodating intraocular lenses for the upcoming Group Two first-in-human clinical surgeries in Mexico City. The redesigned one-piece lens incorporates advancements intended to enhance accommodative performance, surgical handling, reliability and manufacturing scalability. The new design also eliminates internal interface materials, with no air, water or oil.
Key Highlights:
- Clinical lenses are expected to ship from Germany to Mexico City in early September.
- Recruitment for Group Two patients is expected to begin shortly.
- Group One patients are completing their important 12-month follow-up visits.
- Ocumetics has determined that a new provisional patent filing is appropriate to protect intellectual property associated with the next-generation design.
These milestones will provide Ocumetics with additional clinical data as the Company continues advancing the Ocumetics Lens toward its ultimate commercial objective.
August 24, 2026 : Ocumetics Completes $3.11 Million Financing
Ocumetics has completed the third and final tranche of its previously announced private placement, bringing total gross proceeds from the offering to $3,110,130. The final tranche consisted of 405,000 units issued at $0.40 per unit for gross proceeds of $162,000. This financing represents an important milestone for Ocumetics and positions the Company to advance the next stages of its clinical and regulatory program. Proceeds are expected to support:
- Continuing first-in-human clinical trials.
- Group Two surgeries planned for Mexico City this fall.
- Ongoing research and development and general working capital.
- Preparations for an FDA Investigational Device Exemption application targeted for early 2027.
November 22, 2024 : Ocumetics Provides Update on Accommodative Intraocular Lens Internal Tests
Ocumetics Technology Corp. is pleased to provide an update on internal test results of its recently manufactured accommodative intraocular lenses ("AIOL").
During internal testing of lenses manufactured for its upcoming first in human ("FIH") trials, the design team identified an opportunity to improve the lens design to further enhance its performance and safety profile.
To manufacture the optimized lenses, Ocumetics must re-order raw materials, create new lens molds, and then manufacture the lenses. Thereafter, Ocumetics will perform final internal tests to ensure that safety, efficacy and regulatory standards are met or exceeded, in keeping with its quality assurance protocols. Currently, the company estimates this process will result in a 45 to 60-day delay in its previously estimated FIH surgery date.
May 18, 2022 : Ocumetics Update on the Status of Preclinical Studies for the Bionic Lens
Since January 2022, Ocumetics has been busy undertaking studies using cadaver donor eyes to determine how Ocumetics' optical technologies would fit in the human eye. These studies have led to design enhancements to perfect how the Bionic Lens conforms to the lens capsular bag of the human eye.
The studies, and resulting design enhancements, were supervised by Ocumetics' regulatory approval expert, Dr. Barbara Fant, Ocumetics' founder and Chief Scientific Officer, Dr. Garth Webb, and Chief Medical Officer, Dr. Doyle Stulting.
The ergonomics of installing the optical technologies has also been an emphasis over the past 4-6 weeks.
January 10, 2022 : Ocumetics Update on the Status of Preclinical Studies for the Bionic Lens
The preclinical studies for the Bionic Lens, consisting of the lens retainer and the lens itself, commenced on October 22, 2021. The preclinical studies are planned in three stages:
| Stage | Description | Status | Expected completion |
|---|---|---|---|
| 1 | Test the Bionic Lens retainer for structural integrity and ease of insertion by the surgeon. | Commenced Oct 22/21. Analysis completed in October 2021. | Study completed Oct/21. Design improvements completed Dec/21. |
| 2 | Test the Bionic lens retainer with a standard lens used in a typical cataract procedure. | Scheduled to begin February 25, 2022. | Research report expected June/22. |
| 3 | Test the Bionic Lens retainer and optic element together. | Scheduled to begin March 25, 2022. | Research report expected June/22. |
Successful preclinical studies will be followed by Phase 1 human clinical trials, starting with a planned Proof-of-Concept study in the Fall of 2022.
Frequently Asked Questions
Is the Bionic Lens available to buy or receive from a doctor yet
No, the device remains investigational and has only been placed in a small number of clinical study patients, so it cannot be requested or purchased through a regular eye clinic at this time.
Which country is hosting the human clinical surgeries
The first-in-human surgeries are being carried out at a clinical facility in Mexico City, which performed the Group One operations in Fall 2025 and is preparing for Group Two in Fall 2026.
What is the difference between Group One and Group Two patients
Group One focused solely on the safety of the lens, while Group Two is designed to study safety along with both distance and near vision performance of the newer lens design.
How much money has Ocumetics raised for its clinical program
Ocumetics completed a private placement that brought total gross proceeds to just over 3.11 million dollars, with funds supporting trials, the Group Two surgeries, research, and regulatory preparations.
When is Ocumetics planning to approach the FDA
The company is preparing an FDA Investigational Device Exemption application that it has targeted for early 2027 as part of its regulatory pathway.
Does the lens contain any liquids or gases inside it
No, the redesigned one-piece next-generation lens removes all internal interface materials and contains no air, no water, and no oil.
Where are the clinical lenses manufactured
The next-generation clinical lenses are manufactured in Germany and then shipped to the clinical facility in Mexico City for the surgeries.
Should the early trial results be treated as proof that the lens works
No, the company stresses that these are early first-in-human results that should not be read as established proof of safety or efficacy, since more patients, more data, and longer follow-up are still needed.
Ocumetics Technology Corp.
Ocumetics Technology Corp. is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry - the Bionic Lens. The Bionic Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. It allows the eye's natural muscle activity to shift focus from distance to near.
Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.
Dr. Garth Webb - Founder of Ocumetics Technology Corporation
Dr. Garth Webb has an inherent background in the science of sight. With over 40 years of optometry experience, Dr. Webb shifted his attention to product development and soon after became the sole innovator of the Bionic Lens. Coining the term "Human Visual Experience", he has completely changed the way people once viewed virtual reality through integration of basic science with physiological options and digital communications.
Insights, Analysis, and Developments
Editorial Note: What sets this account apart is its honesty about timelines, since each update quietly resets expectations rather than overselling them, from the 2022 Proof of Concept target to the 2024 decision to redesign the lens before any human implantation. That candor matters because the potential audience is enormous - the millions affected by cataracts and age related focus loss who would gain the most from a lens that accommodates like a young, healthy eye. Readers should note the leadership continuity and change across the reports, with founder Dr. Garth Webb and a rotating slate of executives and regulatory experts steering the science, and they should treat the projected surgery dates as moving targets tied to raw material reorders, new molds, and repeated internal testing rather than fixed promises.
Author Credentials: Ian is the founder and Editor-in-Chief of Disabled World, a leading resource for news and information on disability issues. With a global perspective shaped by years of travel and lived experience, Ian is a committed proponent of the Social Model of Disability, a transformative framework developed by disabled activists in the 1970s that emphasizes dismantling societal barriers rather than focusing solely on individual impairments. His work reflects a deep commitment to disability rights, accessibility, and social inclusion. To learn more about Ian's background, expertise, and accomplishments, visit his full biography.